As China Volume Purchase Builds, Novartis Scrambles To Launch New Products

The Largest VBP Looming

China’s latest volume-based purchase round is also the largest ever, covering more drugs and many of them are the widest-prescribed products. Novartis feels the pinch of price pressures but emphasizes a shift to new product launches.

China growth
CHINA THIRD ROUND VBP TO COVER 56 PRODUCTS INCLUDING DIOVAN FROM NOVARTIS • Source: Shutterstock

Entering July, China is getting ready to launch a new round of its volume-based purchase (VBP) scheme for many drugs, including some extensively prescribed cardiovascular treatments in the country. The products covered include antidiabetics, anticancers and central nervous system drugs including metformin, ibuprofen and valsartan.

Already, provincial authorities in Hunan Province have required medical institutions to report their procurement volumes of the products, and another...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip